On Friday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was 11.75% up from the session before settling in for the closing price of $253.54. A 52-week range for ALNY has been $141.98 – $304.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 63.53%. When this article was written, the company’s average yearly earnings per share was at 18.93%. With a float of $124.34 million, this company’s outstanding shares have now reached $129.29 million.
Let’s determine the extent of company efficiency that accounts for 2230 employees. In terms of profitability, gross margin is 85.62%, operating margin of -7.87%, and the pretax margin is -16.79%.
Alnylam Pharmaceuticals Inc (ALNY) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Alnylam Pharmaceuticals Inc stocks. The insider ownership of Alnylam Pharmaceuticals Inc is 4.41%, while institutional ownership is 95.03%. The most recent insider transaction that took place on Mar 21 ’25, was worth 1,231,485. Before that another transaction happened on Mar 03 ’25, when Company’s CSO & EVP, Head of Research sold 1,911 for $243.73, making the entire transaction worth $465,772. This insider now owns 14,345 shares in total.
Alnylam Pharmaceuticals Inc (ALNY) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.93% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
You can see what Alnylam Pharmaceuticals Inc (ALNY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.17, a number that is poised to hit -0.93 in the next quarter and is forecasted to reach 1.50 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Looking closely at Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), its last 5-days average volume was 1.28 million, which is a jump from its year-to-date volume of 0.75 million. As of the previous 9 days, the stock’s Stochastic %D was 76.43%. Additionally, its Average True Range was 11.77.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 83.72%, which indicates a significant decrease from 89.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.74% in the past 14 days, which was higher than the 43.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $256.65, while its 200-day Moving Average is $252.45. However, in the short run, Alnylam Pharmaceuticals Inc’s stock first resistance to watch stands at $294.85. Second resistance stands at $306.37. The third major resistance level sits at $323.29. If the price goes on to break the first support level at $266.41, it is likely to go to the next support level at $249.49. Should the price break the second support level, the third support level stands at $237.97.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are 129,457K outstanding shares of the company, which has a market capitalization of 36.86 billion. As of now, sales total 2,248 M while income totals -278,160 K. Its latest quarter income was 593,170 K while its last quarter net income were -83,760 K.
